IP Library Granted Patent US 7,048,950
Granted Patent B2
US 7,048,950 · App. 10/843,277 · Granted May 23, 2006

Use of Emu Oil and its various fractions as a carrier for antifungal, antibacterial, and antiviral medications and preparations

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,048,950
App. No.
10/843,277
Granted
May 23, 2006
Kind
B2
Abstract

An animal-derived lipid is disclosed that is useful as a carrying agent for anti-microbial formulations. Pharmaceutical and other preparations including Emu Oil are also described as profoundly useful components in anti-bacterial, anti-fungal, and anti-viral treatments. This lipid material is extracted from the Emu ( Dromais Novae - Hollandiae ), an indigenous bird of Australia and New Zealand. The present invention also discloses therapeutic compositions comprising Emu Oil in combination with an extracellular product of Bacillus coagulans or Pseudomonas lindbergii strain, comprising a supernatant or filtrate of said culture suitable for topical application to the skin or mucosal membranes of a mammal, which are utilized to inhibit the growth of bacterium, yeast, fungi, virus, and combinations thereof. Additionally, the aforementioned therapeutic composition may also include an anti-microbial, anti-mycotic, and/or anti-viral agent. The present invention also discloses methods of treatment and therapeutic systems for inhibiting the growth of bacterium, yeast, fungi, virus, and combinations thereof, by topical application of therapeutic compositions comprising Emu Oil in combination with an extracellular product of Bacillus coagulans or Pseudomonas lindbergii strain suitable for topical application to the skin or mucosal membranes of a mammal. Similarly, the aforementioned method may also employ a therapeutic composition additionally containing an anti-microbial, anti-mycotic, and/or anti-viral agent.

Claims (8)

1. A composition comprising terbinafine in a pharmaceutically-acceptable carrier which is suitable for topical application to skin or a mucous membrane of a mammal and Emu Oil.

2. The composition of claim 1 , wherein said carrier is selected from a group comprising an emulsion, cream, lotion, gel, oil, ointment, suspension, aerosol spray, powder, aerosol powder, or semi-solid formulation.

3. The composition of claim 1 , wherein the Emu Oil comprises approximately 0.5% to approximately 99.9%, by weight of said composition.

4. The composition of claim 1 , wherein the Emu Oil comprises approximately 10% to approximately 75%, by weight of said composition.

5. The composition of claim 1 , wherein the Emu Oil comprises approximately 25% to approximately 60%, by weight of said composition.

6. The composition of claim 1 , further comprising one or more compounds selected from the group comprising dimethyl sulfoxide (DMSO), methylsulfonylmethane (MSM), and Lignisul MSM.

7. The composition of claim 1 , further comprising a non-microbially-derived, anti-microbial compound selected from the group consisting of amphotericin B, carbol-fuchsin, ciclopirox, clotrimzole, econazole, haloprogin, ketoconazole, mafenide, miconazole, naftifine, nystatin, oxiconazole, silver sulfadiazine, sulconazole, tioconazole, tolnafiate, and undecylenic acid.

8. The composition of claim 1 , further comprising a non-microbially-derived, anti-fungal vaginal compound selected from the group consisting of butoconazle, clotrimazole, econazole, gentian violet, miconazole, nystatin, terconazole and tioconazole.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Sep 12, 2017
From: SILICON VALLEY BANK
To: GANEDEN BIOTECH, INC.
Reel/Frame 043822/0897 →
SECURITY AGREEMENT Recorded Oct 10, 2012
From: GANEDEN BIOTECH, INC.
To: SILICON VALLEY BANK
Reel/Frame 029103/0069 →
RELEASE OF SECURITY INTEREST Recorded Dec 6, 2007
From: MIDCAP CREDIT, LLC
To: GANEDEN BIOTECH, INC.
Reel/Frame 020196/0851 →
SECURITY INTEREST Recorded Dec 23, 2005
From: GANEDEN BIOTECH, INC.
To: MIDCAP CREDIT, LLC
Reel/Frame 017136/0820 →